Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2014

Wakimoto Hiroaki, Tanaka Shota, Curry William T, Loebel Franziska, Zhao Dan, Tateishi Kensuke, Chen Juxiang, Klofas Lindsay K, Lelic Nina, Kim James C, Dias-Santagata Dora, Ellisen Leif W, Borger Darrell R, Fendt Sarah-Maria, Vander Heiden Matthew G, Batchelor Tracy T, Iafrate A John, Cahill Daniel P, Chi Andrew S

Abstract excerpt

PURPOSE: Isocitrate dehydrogenase (IDH) gene mutations occur in low-grade and high-grade gliomas. We sought to identify the genetic basis of malignant phenotype heterogeneity in IDH-mutant gliomas. METHODS: We prospectively implanted tumor specimens from 20 consecutive IDH1-mutant glioma resections into mouse brains and genotyped all resection specimens using a CLIA-certified molecular panel. Gliomas with cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gas Chromatography-Mass Spectrometry

Share to Glioma

Share to Heterografts

Share to In Situ Hybridization, Fluorescence

Share to Isocitrate Dehydrogenase

Share to Kaplan-Meier Estimate

Share to Oncogenes

Source

Open in PubMed Open full text

Identifiers

PMID: 24714777
DOI: 10.1158/1078-0432.CCR-13-3052
PMCID: PMC4070445

Genes

IDH1
CIC
MET
PDGFRA
KRAS
MYC
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.PMID 24714777Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.Semantic proximity Read ↗

From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.Semantic proximity Read ↗

IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?Semantic proximity Read ↗

Genetic alterations and signaling pathways in the evolution of gliomas.Semantic proximity Read ↗

Advances in the treatment of IDH-mutant gliomas.Semantic proximity Read ↗

Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade.Semantic proximity Read ↗

Low-Grade Gliomas: A New Mutation, New Targeted Therapy, and Many Questions.Semantic proximity Read ↗

Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.Semantic proximity Read ↗

Generation, characterization and drug sensitivities of twelve patient-derived IDH1 mutant glioma cell culturesSemantic proximity Read ↗

Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.Semantic proximity Read ↗

Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.